Literature DB >> 25943066

Next generation prophylactic human papillomavirus vaccines.

John T Schiller1, Martin Müller2.   

Abstract

The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1 (the major papillomavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe, effective, and well established prophylactic vaccines. However, they have some inherent limitations, including a fairly high production and delivery cost, virus-type restricted protection, and no reported therapeutic activity, which might be addressed with the development of alternative dosing schedules and vaccine products. A change from a three-dose to a two-dose protocol for the licensed HPV vaccines, especially in younger adolescents (aged 9-13 years), is underway in several countries and is likely to become the future norm. Preliminary evidence suggests that recipients of HPV vaccines might derive prophylactic benefits from one dose of the bivalent vaccine. Substantial interest exists in both the academic and industrial sectors in the development of second-generation L1 VLP vaccines in terms of cost reduction-eg, by production in Escherichia coli or alternative types of yeast. However, Merck's nonavalent vaccine, produced via the Saccharomyces cerevisiae production system that is also used for their quadrivalent vaccine, is the first second-generation HPV VLP vaccine to be available on the market. By contrast, other pharmaceutical companies are developing microbial vectors that deliver L1 genes. These two approaches would add an HPV component to existing live attenuated vaccines for measles and typhoid fever. Prophylactic vaccines that are based on induction of broadly cross-neutralising antibodies to L2, the minor HPV capsid protein, are also being developed both as simple monomeric fusion proteins and as virus-like display vaccines. The strong interest in developing the next generation of vaccines, particularly by manufacturers in middle-to-high income countries, increases the likelihood that vaccine production will become decentralised with the hope that effective HPV vaccines will be made increasingly available in low-resource settings where they are most needed.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25943066     DOI: 10.1016/S1470-2045(14)71179-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  41 in total

1.  HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.

Authors:  Douglas R Lowy
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

2.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

3.  HPV vaccines: Global perspectives.

Authors:  Gaurav Gupta; Reinhard Glueck; Pankaj R Patel
Journal:  Hum Vaccin Immunother       Date:  2017-03-31       Impact factor: 3.452

4.  Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures.

Authors:  N Sanjib Banerjee; Hsu-Kun Wang; James R Beadle; Karl Y Hostetler; Louise T Chow
Journal:  Antiviral Res       Date:  2017-12-26       Impact factor: 5.970

Review 5.  [Prevention of HPV-induced diseases by prophylactic vaccination].

Authors:  Ulrike Wieland; Alexander Kreuter
Journal:  Hautarzt       Date:  2020-12-18       Impact factor: 0.751

Review 6.  Adjuvant formulations for virus-like particle (VLP) based vaccines.

Authors:  Velasco Cimica; Jose M Galarza
Journal:  Clin Immunol       Date:  2017-08-03       Impact factor: 3.969

Review 7.  [Genital warts in HIV-infected individuals].

Authors:  U Wieland; A Kreuter
Journal:  Hautarzt       Date:  2017-03       Impact factor: 0.751

8.  Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.

Authors:  Anna Godi; Dolcibella Boampong; Busayo Elegunde; Kavita Panwar; Maxime Fleury; Shaowei Li; Qinjian Zhao; Ningshao Xia; Neil D Christensen; Simon Beddows
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

Review 9.  Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.

Authors:  Mariam El-Zein; Lyndsay Richardson; Eduardo L Franco
Journal:  J Clin Virol       Date:  2015-11-18       Impact factor: 3.168

10.  Personalized vaccination against ovarian cancer: what are the possibilities?

Authors:  Janos L Tanyi; Erin George
Journal:  Expert Rev Vaccines       Date:  2018-11-07       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.